在放射治疗后不确定潜力的克隆性血液形成
Shelby A Crants1, Sydney S Olson2, Yajing Li3
1Vanderbilt University School of Medicine, Nashville, Tennessee.
International journal of radiation oncology, biology, physics
|October 25, 2025
概括
放射治疗 (RT) 增加了不确定潜力 (CHIP) 克隆性血液形成的风险,这种情况与血液癌症有关. 较高的辐射剂量和特定的技术,如立体RT,会增加这种风险.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
背景情况:
- 不确定潜力的克隆性血液形成 (CHIP) 是一种与血液恶性瘤和心血管疾病风险增加相关的疾病.
- 放射治疗 (RT) 是已知的CHIP风险因素,但具体的贡献因素仍然不清楚.
研究的目的:
- 调查放射治疗参数与CHIP患病率之间的关联.
- 确定影响CHIP开发的特定RT因素,如剂量,技术和辐射地点.
主要方法:
- 分析了489名癌症患者的队列,这些患者在血液样本采集前至少6个月接受了RT.
- 排除标准包括先前的血液恶性瘤或细胞毒性化疗.
- 针对性DNA测序被用于检测CHIP相关突变,其流行率与854名非RT患者的对照队列相比.
主要成果:
- 在接受RT的患者中,CHIP被检测到23%,与对照组相比,患病率明显高 (OR,1.49).
- CHIP风险与生物等效辐射剂量 (r = 0.64,P < .001) 有正相关性,并与立体技术相关 (OR,2.56).
- 在患有原发性肺癌的患者和接受脊椎辐射的患者中观察到更高的CHIP患病率.
结论:
- 之前的放射治疗与克隆性血液形成的风险增加有关.
- 较高的生物等效辐射剂量,立体技术和脊柱RT特别与CHIP风险增加有关.
- 这些发现突出了特定的RT模式,可能需要对CHIP发展进行更密切的监测.
相关概念视频
01:19Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
01:34Production of Formed Elements
3.6K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
Most HSCs commit to...
3.6K
01:21Lineage Commitment
4.1K
Commitment is the process whereby stem cells:
4.1K
01:21Hematopoiesis
8.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.7K
01:21Stem Cell Therapy for Tissue Regeneration
4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
01:01Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K